A new dry eye device, which claims to treat evaporative dry eye, meibomian gland dysfunction (MGD) and the less common and more difficult to treat aqueous deficient dry eye has arrived in New Zealand.
Rexon-Eye is a new dry eye device adapted from technology originally developed to speed wound healing, said Jeremy Rebion from Eyetek, the first Australasian distributor to bring the relatively new device Downunder on behalf of its manufacturer, Italian-based Resono Ophthalmic.
Unlike intense pulsed light (IPL) machines, that were originally developed for the anti-wrinkle world and now dominate MGD treatment, the Rexon-Eye is a non-invasive treatment, requiring no external cooling systems, which uses electrodes to stimulate the metabolism and regeneration of cells. Resono calls this operation principle quantum molecular resonance. QMR delivers alternate electric current patterns at frequencies ranging from 4MHz to 64MHz that resonate with biological tissue molecular bindings which reactivates their correct physiological behaviour and restores health, it says.
Unveiling the device for the first time in New Zealand, optometrist Ryan Mahmoud from NVision in Auckland, which specialises in treating dry eye patients, said he was impressed by the literature and how QMR technology had been used successfully in other areas of the body for chronic wound healing.
“I mainly see dry eye patients, so I see differences in severity and what people need. There is a cohort of patients who have mixed MGD and aqueous deficient dry eye, so I see this as a good option.”
